Janus Henderson Group
LRMR icon

Janus Henderson Group’s Larimar Therapeutics LRMR Stock Holding History

Janus Henderson Group’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-5,571,963
Closed -$13.1M – 2469
2025
Q1 		$13.1M Sell
5,571,963
-871,323
-14% -$2.75M 0.01% 657
2024
Q4 		$24.9M Buy
6,443,286
+876,431
+16% +$5.79M 0.01% 533
2024
Q3 		$36.4M Buy
5,566,855
+1,189,467
+27% +$9.56M 0.02% 454
2024
Q2 		$31.6M Buy
4,377,388
+356,423
+9% +$2.73M 0.02% 483
2024
Q1 		$30.5M Buy
4,020,965
+1,379,900
+52% +$10.8M 0.02% 486
2023
Q4 		$12M Buy
2,641,065
+179,603
+7% +$606K 0.01% 634
2023
Q3 		$9.71M Buy
2,461,462
+1,015,736
+70% +$3.84M 0.01% 670
2023
Q2 		$4.53M Buy
1,445,726
+375,295
+35% +$1.53M ﹤0.01% 888
2023
Q1 		$4.86M Buy
1,070,431
+143,162
+15% +$748K ﹤0.01% 882
2022
Q4 		$3.82M Buy
927,269
+127,269
+16% +$434K ﹤0.01% 920
2022
Q3 		$2.57M Buy
800,000
+50,932
+7% +$128K ﹤0.01% 987
2022
Q2 		$1.48M Sell
749,068
-296,177
-28% -$875K ﹤0.01% 1152
2022
Q1 		$4.22M Buy
1,045,245
+310,133
+42% +$2.03M ﹤0.01% 1047
2021
Q4 		$7.92M Buy
735,112
+93,997
+15% +$1.05M ﹤0.01% 951
2021
Q3 		$7.46M Buy
641,115
+40,155
+7% +$482K ﹤0.01% 960
2021
Q2 		$5.89M Buy
600,960
+458,613
+322% +$5.18M ﹤0.01% 1031
2021
Q1 		$2.08M Buy
142,347
+3,602
+3% +$65.4K ﹤0.01% 1183
2020
Q4 		$2.97M Sell
138,745
-24,854
-15% -$498K ﹤0.01% 1063
2020
Q3 		$2.54M Buy
+163,599
New +$2.07M ﹤0.01% 1020

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Janus Henderson Group's LRMR Position: Q2 2025 in Review

Janus Henderson Group sold out of Larimar Therapeutics (LRMR) in Q2 2025, closing a stake of 5,571,963 shares — an estimated $13.1M sold.

Janus Henderson Group first reported a position in LRMR in Q3 2020 and held it in 19 quarters. The position peaked at $36.4M in Q3 2024. 116 funds tracked by Wall St. Rank hold LRMR as of Q2 2025.

  • Janus Henderson Group reported no remaining Larimar Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Janus Henderson Group sold 5,571,963 Larimar Therapeutics shares in Q2 2025, an estimated $13.1M.
  • Janus Henderson Group first reported a position in Larimar Therapeutics in Q3 2020 and held it in 19 quarters.
  • Janus Henderson Group's Larimar Therapeutics position peaked at $36.4M in Q3 2024.
  • 116 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2025.

Based on Janus Henderson Group's 13F filing for Q2 2025, filed 14 Aug 2025.